Deutsche Bank AG purchased a new position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) in the second quarter, according to its most recent filing with the SEC. The firm purchased 335,980 shares of the medical instruments supplier's stock, valued at approximately $51,153,000. Deutsche Bank AG owned 0.49% of Insulet at the end of the most recent quarter.
Other hedge funds have also recently made changes to their positions in the company. Mitsubishi UFJ Trust & Banking Corp boosted its stake in Insulet by 26.5% during the fourth quarter. Mitsubishi UFJ Trust & Banking Corp now owns 43,921 shares of the medical instruments supplier's stock worth $12,484,000 after acquiring an additional 9,206 shares in the last quarter. OP Asset Management Ltd acquired a new position in shares of Insulet during the first quarter valued at about $1,513,000. SEB Asset Management AB bought a new position in shares of Insulet during the 1st quarter worth about $24,700,000. Swedbank AB grew its stake in shares of Insulet by 11.0% in the 4th quarter. Swedbank AB now owns 85,988 shares of the medical instruments supplier's stock valued at $24,441,000 after buying an additional 8,500 shares during the period. Finally, Strs Ohio grew its stake in shares of Insulet by 36.0% in the 4th quarter. Strs Ohio now owns 22,680 shares of the medical instruments supplier's stock valued at $6,447,000 after buying an additional 6,003 shares during the period.
Key Insulet News
Here are the key news stories impacting Insulet this week:
- Negative Sentiment: Multiple law firms announced or promoted a securities class action against Insulet and certain executives. The complaints allege that the company made materially false or misleading statements about manufacturing controls, product quality, and the safety and reliability of Omnipod devices. The allegations have not been proven in court. Pomerantz class action announcement
- Negative Sentiment: The investor notices link the case to two Omnipod medical-device corrections and claim that related disclosures contributed to a substantial decline in Insulet’s stock. One notice cited a move from $236.07 to $146.01 across the alleged corrective disclosures, or losses exceeding $90 per share for some investors. SueWallSt investor notice
- Negative Sentiment: The legal overhang intensified as several firms—including Robbins Geller, Faruqi & Faruqi, Rosen, Bronstein Gewirtz & Grossman, Bernstein Liebhard, Glancy Prongay, Robbins LLP, Levi & Korsinsky, and Portnoy—urged affected shareholders to seek lead-plaintiff status or evaluate potential recovery. The deadline to move for lead-plaintiff appointment is August 31, 2026. Robbins Geller deadline announcement
Wall Street Analysts Forecast Growth
PODD has been the topic of a number of research reports. BTIG Research downgraded Insulet from a "buy" rating to a "neutral" rating in a research note on Thursday, August 6th. The Goldman Sachs Group reissued a "buy" rating and issued a $205.00 price objective on shares of Insulet in a research note on Wednesday, May 27th. TD Cowen decreased their price objective on Insulet from $294.00 to $144.00 and set a "hold" rating for the company in a report on Thursday, August 6th. Oppenheimer lowered Insulet from an "outperform" rating to a "market perform" rating in a research report on Wednesday, August 5th. Finally, Canaccord Genuity Group cut their target price on Insulet from $249.00 to $179.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. Fourteen investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $195.40.
Check Out Our Latest Analysis on Insulet
Insider Transactions at Insulet
In other news, Director Timothy C. Stonesifer acquired 2,790 shares of Insulet stock in a transaction on Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, with a total value of $400,392.90. Following the transaction, the director owned 9,041 shares of the company's stock, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.36% of the company's stock.
Insulet Price Performance
Shares of NASDAQ:PODD opened at $146.87 on Friday. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The stock has a market cap of $10.19 billion, a PE ratio of 27.45, a price-to-earnings-growth ratio of 1.19 and a beta of 1.10. The stock's fifty day simple moving average is $154.70 and its two-hundred day simple moving average is $185.07. Insulet Corporation has a 1-year low of $126.40 and a 1-year high of $354.88.
Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.19. The firm had revenue of $801.70 million during the quarter, compared to analyst estimates of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business's revenue was up 23.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, analysts forecast that Insulet Corporation will post 6.51 EPS for the current fiscal year.
Insulet Company Profile
(
Free Report)
Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.
The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
